Secondary Logo

Journal Logo

Concomitant Epstein-Barr Virus (EBV)-Positive B-Cell and EBV-Negative T-Cell Posttransplant Lymphoproliferative Disorders After Renal Allografting: Pathogenetic Implications

Au, Wing-Yan1; Lam, Man-Fei1; Pang, Annie1; Leung, Rock Y. Y.2; Kwong, Yok-Lam1

doi: 10.1097/TP.0b013e31823915f6
Letter to the Editor
Free
SDC

1Department of Medicine, Queen Mary Hospital, Hong Kong, China

2Department of Pathology, Queen Elizabeth Hospital, Hong Kong, China

The authors declare no funding or conflicts of interest.

Address correspondence to: Wing-Yan Au, UMU, 4/F, Professorial Block, Queen Mary Hospital, Pokfulam Road, Hong Kong, People's Republic of China.

E-mail: auwing@hotmail.com

W.-Y.A. participated in research design and writing; M.-F.L. participated in writing; A.P. participated in research performance; R.Y.Y.L. participated in management and writing; and Y.-L.K. participated in research design and writing.

Received 5 September 2011.

Accepted 21 September 2011.

Posttransplant lymphoproliferative disorders (PTLD) develop in organ allograft recipients because of the immunodeficient state induced by immunosuppressive drugs used to prevent graft rejection. In B-cell PTLD, Epstein-Barr virus (EBV) plays an important etiologic role, as unchecked EBV replication in infected B cells ultimately leads to neoplastic transformation. In T-cell PTLD, however, EBV is often not involved, so that it remains unclear what the pathogenetic mechanism(s) may be.

A 30-year-old man received a cadaveric renal allograft for chronic glomerulonephritis. Five years later, he presented with a generalized seizure. A computered tomography showed a 4-cm frontal lobe lesion (arrow, Fig. 1A). Biopsy showed monotonous sheets of malignant large lymphoid cells, expressing CD20 and EBV-encoded small RNA, consistent with monomorphic B-cell PTLD. Further staging investigations, including computed tomography of thorax and abdomen and bilateral marrow biopsies, were negative. Furthermore, circulating EBV DNA as a surrogate biomarker (1) was negative, showing that there was no extracranial involvement. Cyclosporine was stopped. Local radiotherapy (30 Gy) and intrathecal anti-CD20 antibody rituximab (2) (30 mg twice weekly×eight doses) produced a complete remission. However, graft rejection ensued, requiring hemodialysis and erythropoietin (EPO: 4000 IU weekly) treatment. Six months later, a blood count showed hemoglobin (Hb): 4.0 g/dL, undetectable reticulocytes, white cell count: 3×109/L, 15% large granular lymphocytes (LGLs) (Fig. 1B), and platelet count: 108×109/L. A marrow biopsy showed pure red cell aplasia (PRCA) with virtually absent erythropoiesis (Fig. 1C). Serologic tests for parvovirus B19 and antierythropoietin antibody were negative.

FIGURE 1.

FIGURE 1.

The abnormal LGLs were CD3+ve, CD4−ve, CD8+ve, and EBV-encoded small RNA-negative. To confirm the clonal nature of the T-LGLs, polymerase chain reaction (PCR) for T-cell receptor gamma (TCRγ) gene was performed as previously described (3). Clonally rearranged TCRγ gene was demonstrated, confirming the presence of T-LGL leukemia (Fig. 1D). Therefore, the overall diagnosis was T-LGL leukemia with PRCA, a well-defined clinical syndrome (4). To delineate the time when the T-LGL leukemia first developed, the clonal TCRγ PCR product was sequenced, and a clonal-specific primer was designed (Fig. 1D). With clonal specific PCR, the neoplastic T-LGL leukemia clone was in fact already present at the time of diagnosis of the B-cell PTLD (Fig. 1D).

Treatment with the anti-CD52 antibody alemtuzumab (30 mg×three doses) resulted in a rapid normalization of the Hb. PCR also showed that a molecular remission was attained. At the latest follow-up 28 months postalemtuzumab, his blood counts showed Hb: 14.2 g/dL, white cell count: 3.9×109/L, and platelet count: 128×109/L.

EBV-positive B-cell lymphoproliferative diseases are the prototype of PTLD, developing usually early posttransplantation. However, the pathogenesis of EBV-negative lymphoid malignancies posttransplantation remains obscure. While some can be coincidental lymphomas, many EBV-negative PTLD respond to reduction of immunosuppression, implying that the pathogenesis may be similar to EBV-positive PTLD (5). T-LGL leukemia has been described as a T-cell PTLD (6–8). As these cases including ours were all EBV-negative, their relationship with the organ allograft and the immunosuppression remains undefined. De novo T-LGL leukemia is thought to develop because of prolonged antigen stimulation (9). In our case, the renal allograft was an obvious source of chronic antigen stimulation. Interestingly, T-LGL proliferation has also been described in patients with an underlying B-cell lymphoid malignancy, indicating that the neoplastic B cells may also be a source of antigenic stimulation (10).

Our case was instructive in several ways. The concomitant presence of a B-cell PTLD and the T-LGL leukemic clone suggested that the latter might have arisen because of chronic antigenic stimulation, possibly from the B-cell lymphoma. On withdrawal of cyclosporine, the T-LGL leukemia did not regress, showing further that the leukemia was unrelated to immunosuppression. In fact, cyclosporine is a very effective treatment for T-LGL leukemia, (4) and its withdrawal might have been the reason why the T-LGL leukemia became clinically manifest later. Hence, the pathogenetic mechanisms of the B-cell and T-cell neoplasms were disparate in our case. Finally, PRCA is the most common manifestation of T-LGL leukemia in our population (4). Effective treatment of T-LGL leukemia with alemtuzumab led to complete recovery of the PRCA.

Wing-Yan Au1

Man-Fei Lam1

Annie Pang1

Rock Y. Y. Leung2

Yok-Lam Kwong1

1Department of Medicine

Queen Mary Hospital, Hong Kong

China

2Department of Pathology

Queen Elizabeth Hospital, Hong Kong

China

Back to Top | Article Outline

REFERENCES

1.Au WY, Pang A, Choy C, et al. Quantification of circulating (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood 2004; 104: 243.
2.van de Glind G, de Graaf S, Klein C, et al. Intrathecal rituximab treatment for pediatric post-transplant lymphoproliferative disorder of the central nervous system. Pediatr Blood Cancer 2008; 50: 886.
3.Au WY, Lam CC, Lie AK, et al. T-cell large granular lymphocyte leukemia of donor origin after allogeneic bone marrow transplantation. Am J Clin Pathol 2003; 120: 626.
4.Kwong YL, Au WY, Leung AY, et al. T-cell large granular lymphocyte leukemia: An Asian perspective. Ann Hematol 2010; 89: 331.
5.Nelson BP, Nalesnik MA, Bahler DW, et al. Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: A distinct entity? Am J Surg Pathol 2000; 24: 375.
6.Feher O, Barilla D, Locker J, et al. T-cell large granular lymphocytic leukemia following orthotopic liver transplantation. Am J Hematol 1995; 49: 216.
7.Gentile TC, Hadlock KG, Uner AH, et al. Large granular lymphocyte leukaemia occurring after renal transplantation. Br J Haematol 1998; 101: 507.
8.Stamatopoulos K, Economidou D, Papadaki T, et al. Large granular lymphocyte leukemia after renal transplantation: An immunologic, immunohistochemical, and genotypic study. Transplantation 2007; 83: 102.
9.Sokol L, Loughran TP Jr. Large granular lymphocyte leukemia. Oncologist 2006; 11: 263.
10.Papadaki T, Stamatopoulos K, Kosmas C, et al. Clonal T-large granular lymphocyte proliferations associated with clonal B cell lymphoproliferative disorders: Report of eight cases. Leukemia 2002; 16: 2167.
© 2011 Lippincott Williams & Wilkins, Inc.